cdk4  (Cell Signaling Technology Inc)

Journal: Molecular Therapy Oncology

Article Title: Dual targeting of PI3K and FGFR or CDK4/6 reveals synergistic responses in HPV-positive and HPV-negative oropharyngeal cancer spheroids

doi: 10.1016/j.omton.2026.201283

Figure Lengend Snippet: Effects of single and combined inhibitors targeting PI3K, FGFR, and CDK4/6 on the viability of CU-OP spheroids For each cell line, (A) CU-OP-2, (B) CU-OP-3, (C) CU-OP-20, and (D) CU-OP-17, subimages (i)–(v) show viability following treatment with the indicated single/combined agents (i, BYL719; ii, JNJ-42756493; iii, PD-0332991; iv, BYL719 + JNJ-42756493; and v, BYL719 + PD-0332991). Subimages (vi) and (vii) display synergy analyses for the combinations BYL719 + JNJ-42756493 (vi) and BYL719 + PD-0332991 (vii). The data is presented as mean ± SD.

Article Snippet: The PI3K, FGFR, and CDK4/6 inhibitors BYL719 (alpelisib), JNJ-42756493 (erdafitinib), and PD-0332991 (palbociclib), respectively, were purchased from TargetMol (San Diego, California, US) at a concentration of 10 mM in DMSO.

Techniques: Spheroids

Journal: Molecular Therapy Oncology

Article Title: Dual targeting of PI3K and FGFR or CDK4/6 reveals synergistic responses in HPV-positive and HPV-negative oropharyngeal cancer spheroids

doi: 10.1016/j.omton.2026.201283

Figure Lengend Snippet: Effects of single chemotherapeutic agents and their combination with a PI3K inhibitor on the viability of CU-OP spheroids For each cell line, (A) CU-OP-2, (B) CU-OP-3, (C) CU-OP-20, and (D) CU-OP-17, subimages (i)–(v) show viability following treatment with the indicated single/combined agents (i, BYL719; ii, cisplatin; iii, docetaxel; iv, BYL719 + cisplatin; and v, BYL719 + docetaxel). Subimages (vi) and (vii) display synergy analyses for the combinations BYL719 + cisplatin (vi) and BYL719 + docetaxel (vii). The data is presented as mean ± SD.

Article Snippet: The PI3K, FGFR, and CDK4/6 inhibitors BYL719 (alpelisib), JNJ-42756493 (erdafitinib), and PD-0332991 (palbociclib), respectively, were purchased from TargetMol (San Diego, California, US) at a concentration of 10 mM in DMSO.

Techniques: Spheroids

Journal: Molecular Therapy Oncology

Article Title: Dual targeting of PI3K and FGFR or CDK4/6 reveals synergistic responses in HPV-positive and HPV-negative oropharyngeal cancer spheroids

doi: 10.1016/j.omton.2026.201283

Figure Lengend Snippet: Effects of single PI3K, FGFR, and CDK4/6 inhibitors and chemotherapeutic agents and their combination with a PI3K inhibitor on CU-OP-2 spheroid growth Representative images of spheroid growth at 72 h after treatment with: (A) PBS (control); (B) single treatment with BYL719 (BYL), JNJ-42756493 (JNJ), PD-0332991 (PD), cisplatin (CIS), and docetaxel (DOC); and (C) their combination with BYL719. The scale bars represent 400 μm.

Article Snippet: The PI3K, FGFR, and CDK4/6 inhibitors BYL719 (alpelisib), JNJ-42756493 (erdafitinib), and PD-0332991 (palbociclib), respectively, were purchased from TargetMol (San Diego, California, US) at a concentration of 10 mM in DMSO.

Techniques: Control

Journal: Molecular Therapy Oncology

Article Title: Dual targeting of PI3K and FGFR or CDK4/6 reveals synergistic responses in HPV-positive and HPV-negative oropharyngeal cancer spheroids

doi: 10.1016/j.omton.2026.201283

Figure Lengend Snippet: Effects of single PI3K, FGFR, and CDK4/6 inhibitors and chemotherapeutic agents and their combination with a PI3K inhibitor on CU-OP-3 spheroid growth Representative images of spheroid growth at 72 h after treatment with: (A) PBS (control); (B) single treatment with BYL719 (BYL), JNJ-42756493 (JNJ), PD-0332991 (PD), cisplatin (CIS), and docetaxel (DOC); and (C) their combination with BYL719. The scale bars represent 400 μm.

Article Snippet: The PI3K, FGFR, and CDK4/6 inhibitors BYL719 (alpelisib), JNJ-42756493 (erdafitinib), and PD-0332991 (palbociclib), respectively, were purchased from TargetMol (San Diego, California, US) at a concentration of 10 mM in DMSO.

Techniques: Control

Journal: Molecular Therapy Oncology

Article Title: Dual targeting of PI3K and FGFR or CDK4/6 reveals synergistic responses in HPV-positive and HPV-negative oropharyngeal cancer spheroids

doi: 10.1016/j.omton.2026.201283

Figure Lengend Snippet: Effects of single PI3K, FGFR, and CDK4/6 inhibitors and their combination with a PI3K inhibitor on CU-OP-2 spheroid migration Representative images of spheroid migration 72 h after treatment with PBS, single BYL719 (BYL), JNJ-42756493 (JNJ), and PD-0332991 (PD) or their combination with BYL719. The scale bars represent 1 mm.

Article Snippet: The PI3K, FGFR, and CDK4/6 inhibitors BYL719 (alpelisib), JNJ-42756493 (erdafitinib), and PD-0332991 (palbociclib), respectively, were purchased from TargetMol (San Diego, California, US) at a concentration of 10 mM in DMSO.

Techniques: Migration

Journal: Molecular Therapy Oncology

Article Title: Dual targeting of PI3K and FGFR or CDK4/6 reveals synergistic responses in HPV-positive and HPV-negative oropharyngeal cancer spheroids

doi: 10.1016/j.omton.2026.201283

Figure Lengend Snippet: Effects of single PI3K, FGFR, and CDK4/6 inhibitors and their combination with a PI3K inhibitor on proliferation and apoptosis in CU-OP-2 and -3 IHC staining of Ki-67 and cleaved caspase-3 in (A) CU-OP-2 and (B) CU-OP-3 spheroids collected 72 h after treatment with PBS, single BYL719 (BYL), JNJ-42756493 (JNJ), and PD-0332991 (PD) or their combination with BYL719. The scale bars represent 100 μm.

Article Snippet: The PI3K, FGFR, and CDK4/6 inhibitors BYL719 (alpelisib), JNJ-42756493 (erdafitinib), and PD-0332991 (palbociclib), respectively, were purchased from TargetMol (San Diego, California, US) at a concentration of 10 mM in DMSO.

Techniques: Immunohistochemistry, Spheroids

Journal: Molecular Therapy Oncology

Article Title: Dual targeting of PI3K and FGFR or CDK4/6 reveals synergistic responses in HPV-positive and HPV-negative oropharyngeal cancer spheroids

doi: 10.1016/j.omton.2026.201283

Figure Lengend Snippet:

Article Snippet: The PI3K, FGFR, and CDK4/6 inhibitors BYL719 (alpelisib), JNJ-42756493 (erdafitinib), and PD-0332991 (palbociclib), respectively, were purchased from TargetMol (San Diego, California, US) at a concentration of 10 mM in DMSO.

Techniques: